126 related articles for article (PubMed ID: 38517826)
21. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer.
Ando S; Kimura H; Iwai N; Shima M; Ando M; Kuriyama T
Anticancer Res; 2001; 21(4B):3085-92. PubMed ID: 11712815
[TBL] [Abstract][Full Text] [Related]
22. Utility of squamous cell carcinoma antigen, carcinoembryonic antigen, Cyfra 21-1 and neuron specific enolase in lung cancer diagnosis: a prospective study from China.
Song WA; Liu X; Tian XD; Wang W; Liang CY; Zhang T; Guo JT; Peng YH; Zhou NK
Chin Med J (Engl); 2011 Oct; 124(20):3244-8. PubMed ID: 22088515
[TBL] [Abstract][Full Text] [Related]
23. The diagnostic value of the combination of carcinoembryonic antigen, squamous cell carcinoma-related antigen, CYFRA 21-1, neuron-specific enolase, tissue polypeptide antigen, and progastrin-releasing peptide in small cell lung cancer discrimination.
Chen Z; Liu X; Shang X; Qi K; Zhang S
Int J Biol Markers; 2021 Dec; 36(4):36-44. PubMed ID: 34709098
[TBL] [Abstract][Full Text] [Related]
24. Acquired renal cystic disease and tumor markers in chronic hemodialysis patients.
Polenakovic M; Sikole A; Dzikova S; Polenakovic B; Gelev S
Int J Artif Organs; 1997 Feb; 20(2):96-100. PubMed ID: 9093887
[TBL] [Abstract][Full Text] [Related]
25. Clinical application of serum tumor abnormal protein combined with tumor markers in lung cancer patients.
Tong H; Dan B; Dai H; Zhu M
Future Oncol; 2022 Apr; 18(11):1357-1369. PubMed ID: 35044835
[TBL] [Abstract][Full Text] [Related]
26. Triple test with tumor markers CYFRA 21.1, HE4, and ProGRP might contribute to diagnosis and subtyping of lung cancer.
Korkmaz ET; Koksal D; Aksu F; Dikmen ZG; Icen D; Maden E; Onder S; Akbiyik F; Emri S
Clin Biochem; 2018 Aug; 58():15-19. PubMed ID: 29729229
[TBL] [Abstract][Full Text] [Related]
27. Serum levels of five tumor markers for lung cancer in patients with chronic renal failure.
Nomura F; Koyama A; Ishijima M; Takano S; Narita M; Nakai T
Oncol Rep; 1998; 5(2):389-92. PubMed ID: 9468564
[TBL] [Abstract][Full Text] [Related]
28. History, molecular features, and clinical importance of conventional serum biomarkers in lung cancer.
Nakamura H; Nishimura T
Surg Today; 2017 Sep; 47(9):1037-1059. PubMed ID: 28229299
[TBL] [Abstract][Full Text] [Related]
29. Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer.
Molina R; Auge JM; Filella X; Viñolas N; Alicarte J; Domingo JM; Ballesta AM
Anticancer Res; 2005; 25(3A):1773-8. PubMed ID: 16033098
[TBL] [Abstract][Full Text] [Related]
30. [Diagnostic values of conventional tumor markers and their combination with chest CT for patients with stageⅠA lung cancer].
Peng Q; Wu N; Huang Y; Zhao SJ; Tang W; Liang M; Ran YL; Xiao T; Yang L; Liang X
Zhonghua Zhong Liu Za Zhi; 2023 Nov; 45(11):934-941. PubMed ID: 37968078
[No Abstract] [Full Text] [Related]
31. The reference intervals for CA125, CA15-3, CA19-9, CA72-4, AFP, CEA, NSE and CYFRA21-1.
Yang J; Tang A; Ma J; Sun X; Ming L
Scand J Clin Lab Invest; 2019; 79(1-2):71-74. PubMed ID: 30727773
[TBL] [Abstract][Full Text] [Related]
32. Identifying the Best Marker Combination in CEA, CA125, CY211, NSE, and SCC for Lung Cancer Screening by Combining ROC Curve and Logistic Regression Analyses: Is It Feasible?
Yang Q; Zhang P; Wu R; Lu K; Zhou H
Dis Markers; 2018; 2018():2082840. PubMed ID: 30364165
[TBL] [Abstract][Full Text] [Related]
33. [Tumor markers in lung cancer].
Niho S; Shinkai T
Gan To Kagaku Ryoho; 2001 Dec; 28(13):2089-93. PubMed ID: 11791391
[TBL] [Abstract][Full Text] [Related]
34. Clinical role of serum tumor markers SCC, NSE, CA 125, CA 19-9, and CYFRA 21-1 in patients with lung cancer.
Sun A
Lab Med; 2023 Nov; 54(6):638-645. PubMed ID: 37052517
[TBL] [Abstract][Full Text] [Related]
35. Tumor markers in patients with chronic renal failure.
Filella X; Cases A; Molina R; Jo J; Bedini JL; Revert L; Ballesta AM
Int J Biol Markers; 1990; 5(2):85-8. PubMed ID: 1704405
[TBL] [Abstract][Full Text] [Related]
36. Prediction of Pleural Invasion in Challenging Non-Small-Cell Lung Cancer Patients Using Serum and Imaging Markers.
Zhu K; Chen L; He C; Lang Y; Kong X; Qu C; Xu S
Dis Markers; 2020; 2020():6430459. PubMed ID: 32089756
[TBL] [Abstract][Full Text] [Related]
37. New and old biomarkers in the differential diagnosis of lung cancer: Pro-gastrin-releasing peptide in comparison with neuron-specific enolase, carcinoembryonic antigen, and CYFRA 21-1.
Mauro C; Passerini R; Spaggiari L; Galetta D; Radice D; Lentati P; Sandri MT
Int J Biol Markers; 2019 Jun; 34(2):163-167. PubMed ID: 30994045
[TBL] [Abstract][Full Text] [Related]
38. Clinical utility of haptoglobin in combination with CEA, NSE and CYFRA21-1 for diagnosis of lung cancer.
Wang B; He YJ; Tian YX; Yang RN; Zhu YR; Qiu H
Asian Pac J Cancer Prev; 2014; 15(22):9611-4. PubMed ID: 25520076
[TBL] [Abstract][Full Text] [Related]
39. Combined detection of estrogen and tumor markers is an important reference factor in the diagnosis and prognosis of lung cancer.
Bai Y; Shen W; Zhu M; Zhang L; Wei Y; Tang H; Zhao J
J Cell Biochem; 2019 Jan; 120(1):105-114. PubMed ID: 30216488
[TBL] [Abstract][Full Text] [Related]
40. Effect of hemodialysis on the concentration of the seven tumor markers carcinoembryonic antigen, alpha-fetoprotein, squamous cell carcinoma-related antigen, neuron-specific enolase, CA 125, CA 19-9 and CA 15-3 in uremic patients.
Odagiri E; Jibiki K; Takeda M; Sugimura H; Iwachika C; Abe Y; Kihara K; Kihara Y; Itou M; Nomura T
Am J Nephrol; 1991; 11(5):363-8. PubMed ID: 1725572
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]